MCID: ADL020
MIFTS: 11

Adult Malignant Mesenchymoma

Categories: Cancer diseases, Nephrological diseases, Rare diseases

Aliases & Classifications for Adult Malignant Mesenchymoma

MalaCards integrated aliases for Adult Malignant Mesenchymoma:

Name: Adult Malignant Mesenchymoma 12 71

Classifications:



External Ids:

Disease Ontology 12 DOID:5894
NCIt 49 C7947
UMLS 71 C0279548

Summaries for Adult Malignant Mesenchymoma

MalaCards based summary : Adult Malignant Mesenchymoma is related to malignant mesenchymoma. The drugs Morphine and Lenograstim have been mentioned in the context of this disorder. Affiliated tissues include lung.

Related Diseases for Adult Malignant Mesenchymoma

Diseases in the Malignant Mesenchymoma family:

Adult Malignant Mesenchymoma

Diseases related to Adult Malignant Mesenchymoma via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 malignant mesenchymoma 10.0

Symptoms & Phenotypes for Adult Malignant Mesenchymoma

Drugs & Therapeutics for Adult Malignant Mesenchymoma

Drugs for Adult Malignant Mesenchymoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 40)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Morphine Approved, Investigational Phase 3 57-27-2 5288826
2
Lenograstim Approved, Investigational Phase 3 135968-09-1
3
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
4
Dactinomycin Approved, Investigational Phase 3 50-76-0 457193 2019
5
Sargramostim Approved, Investigational Phase 3 83869-56-1, 123774-72-1
6
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
7
Mesna Approved, Investigational Phase 3 3375-50-6 598
8
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
9
Topotecan Approved, Investigational Phase 3 123948-87-8, 119413-54-6 60700
10
Trabectedin Approved, Investigational Phase 2, Phase 3 114899-77-3 108150
11
Doxorubicin Approved, Investigational Phase 2, Phase 3 23214-92-8 31703
12 Molgramostim Investigational Phase 3 99283-10-0
13
Camptothecin Experimental Phase 3 7689-03-4
14 Immunosuppressive Agents Phase 3
15 Immunologic Factors Phase 3
16 Anti-Infective Agents Phase 3
17 Tubulin Modulators Phase 3
18 Antirheumatic Agents Phase 3
19 Antimitotic Agents Phase 3
20 topoisomerase I inhibitors Phase 3
21 Adjuvants, Immunologic Phase 3
22 Cactinomycin Phase 3
23 Alkylating Agents Phase 2, Phase 3
24
Liposomal doxorubicin Phase 2, Phase 3 31703
25 Anti-Bacterial Agents Phase 2, Phase 3
26 Antibiotics, Antitubercular Phase 2, Phase 3
27
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
28
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
29
Ifosfamide Approved Phase 2 3778-73-2 3690
30
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
31
Etoposide Approved Phase 2 33419-42-0 36462
32
Carboplatin Approved Phase 2 41575-94-4 10339178 38904 498142
33 Protein Kinase Inhibitors Phase 1, Phase 2
34 Imatinib Mesylate Phase 1, Phase 2 220127-57-1 123596
35 Angiogenesis Inhibitors Phase 2
36
Isophosphamide mustard Phase 2 0
37 Etoposide phosphate Phase 2
38 razoxane Phase 2
39 Cardiotonic Agents Phase 2
40 Protective Agents Phase 2

Interventional clinical trials:

(show all 20)
# Name Status NCT ID Phase Drugs
1 A Phase III Randomized Study of Preoperative Radiotherapy Plus Surgery Versus Surgery Alone for Patients With Retroperitoneal Sarcoma (RPS) Unknown status NCT01344018 Phase 3
2 Randomized Study of Vincristine, Dactinomycin and Cyclophosphamide (VAC) Versus VAC Alternating With Vincristine and Irinotecan (VI) for Patients With Intermediate-Risk Rhabdomyosarcoma (RMS) Unknown status NCT00354835 Phase 3 Irinotecan Hydrochloride;Cyclophosphamide;Vincristine Sulfate
3 Randomised Trial of Post-Operative Radiotherapy Given to Adult Patients With Extremity Soft Tissue Sarcoma [VORTEX] Completed NCT00423618 Phase 3
4 METASTASECTOMY AND CHEMOTHERAPY FOR LUNG METASTASES FROM SOFT TISSUE SARCOMA: A RANDOMIZED PHASE III STUDY (AN INTERGROUP STUDY WITH THE SCANDINAVIAN SARCOMA GROUP) Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
5 Actinomycin D and Vincristine With or Without Radiation Therapy, for Newly Diagnosed Patients With Low-Risk Rhabdomyosarcoma or Undifferentiated Sarcoma: IRS-V Protocol Completed NCT00002995 Phase 3 cyclophosphamide;vincristine sulfate
6 RANDOMISED TRIAL OF ADJUVANT CHEMOTHERAPY WITH HIGH-DOSE DOXORUBICIN, IFOSFAMIDE AND LENOGRASTIM IN HIGH GRADE SOFT TISSUE SARCOMA Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
7 Intensive Multi-Agent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide (IE) and Vincristine/Doxorubicin/Cyclophosphamide (VDC) for Patients With High-Risk Rhabdomyosarcoma Completed NCT00354744 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;irinotecan hydrochloride;vincristine sulfate
8 Randomized Study of Vincristine, Actinomycin-D, and Cyclophosphamide (VAC) Versus VAC Alternating With Vincristine, Topotecan and Cyclophosphamide for Patients With Intermediate Risk Rhabdomyosarcoma Completed NCT00003958 Phase 3 vincristine sulfate;cyclophosphamide;topotecan hydrochloride
9 TRUSTS: A Phase IIB/III Multicenter Study Comparing the Efficacy of TRabectedin Administered as a 3-Hour or 24-Hour Infusion to Doxorubicin in Patients With Advanced or Metastatic Untreated Soft Tissue Sarcoma Terminated NCT01189253 Phase 2, Phase 3 doxorubicin hydrochloride;trabectedin
10 Randomized Phase II Study of Brostallicin (PNU-166196A) Versus Doxorubicin as First Line Chemotherapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma Unknown status NCT00410462 Phase 2 brostallicin;doxorubicin hydrochloride
11 Phase II Evaluation of Temodal (Temozolomide, Schering) in Previously Treated Advanced Sarcomas Unknown status NCT00003718 Phase 2 temozolomide
12 Phase II Study on ET-743 in Advanced Soft Tissue Sarcomas of the Adult Completed NCT00003939 Phase 2 trabectedin
13 Multicenter Parallel Phase II Trial of BI 2536 Administered as One Hour IV Infusion Every 3 Weeks in Defined Cohorts of Patients With Various Solid Tumors. A New Drug Screening Program of the EORTC Network of Core Institutions (NOCI) Completed NCT00526149 Phase 2 BI 2536
14 Dose Finding and Phase II Study of STI 571 in Advanced Soft Tissue Sarcoma Completed NCT00006357 Phase 1, Phase 2 imatinib mesylate
15 A Multicenter Phase II Study of Continuous Dosing of Sunitinib (Sutent®, SU11248) in Non-GIST Sarcomas Completed NCT00474994 Phase 2 sunitinib malate
16 A Phase II "Up-Front Window Study" of Irinotecan (CPT-11) Followed by Multimodal, Multiagent, Therapy for Selected Children and Adolescents With Newly Diagnosed Stage 4/Clinical Group IV Rhabdomyosarcoma: An IRS-V Study Completed NCT00003955 Phase 2 cyclophosphamide;irinotecan hydrochloride;vincristine sulfate
17 A Pilot Phase II Trial Of Irinotecan Plus Carboplatin, And Irinotecan Maintenance Therapy (High-Risk Patients Only), Integrated Into The Upfront Therapy Of Newly Diagnosed Patients With Intermediate - And High-Risk Rhabdomyosarcoma Active, not recruiting NCT00077285 Phase 2 carboplatin;cyclophosphamide;dexrazoxane hydrochloride;doxorubicin hydrochloride;etoposide;ifosfamide;irinotecan hydrochloride;vincristine sulfate
18 Phase II Study of Preoperative Intensity-Modulated Radiation Therapy for Soft-Tissue Sarcomas Terminated NCT00740597 Phase 2
19 Phase I Study To Determine The Safety Of Caelyx (Doxorubin HCI, Pegylated Liposomal) In Combination With Ifosfamide In Previously Untreated Adult Patients With Advanced And/Or Metastatic Soft Tissues Sarcomas Completed NCT00030784 Phase 1 ifosfamide;pegylated liposomal doxorubicin hydrochloride
20 VORTEX-BIOBANK: Prospective Sample Collection for the VORTEX Randomised Radiotherapy Trial in Patients With Extremity Soft Tissue Sarcoma [VORTEX BIOBANK] Unknown status NCT00900211

Search NIH Clinical Center for Adult Malignant Mesenchymoma

Genetic Tests for Adult Malignant Mesenchymoma

Anatomical Context for Adult Malignant Mesenchymoma

MalaCards organs/tissues related to Adult Malignant Mesenchymoma:

40
Lung

Publications for Adult Malignant Mesenchymoma

Variations for Adult Malignant Mesenchymoma

Expression for Adult Malignant Mesenchymoma

Search GEO for disease gene expression data for Adult Malignant Mesenchymoma.

Pathways for Adult Malignant Mesenchymoma

GO Terms for Adult Malignant Mesenchymoma

Sources for Adult Malignant Mesenchymoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....